DE60222296D1 - Impfstoff von umhüllten viren und verfahren zu seiner herstellung - Google Patents

Impfstoff von umhüllten viren und verfahren zu seiner herstellung

Info

Publication number
DE60222296D1
DE60222296D1 DE60222296T DE60222296T DE60222296D1 DE 60222296 D1 DE60222296 D1 DE 60222296D1 DE 60222296 T DE60222296 T DE 60222296T DE 60222296 T DE60222296 T DE 60222296T DE 60222296 D1 DE60222296 D1 DE 60222296D1
Authority
DE
Germany
Prior art keywords
production
virus
purified
rrv
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222296T
Other languages
English (en)
Other versions
DE60222296T2 (de
Inventor
Otfried Kistner
Manfred Reiter
Axel Bruehmann
Noel Barrett
Wolfgang Mundt
Friedrich Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Original Assignee
Baxter Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA filed Critical Baxter Healthcare SA
Publication of DE60222296D1 publication Critical patent/DE60222296D1/de
Application granted granted Critical
Publication of DE60222296T2 publication Critical patent/DE60222296T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60222296T 2001-12-10 2002-12-10 Impfstoff von umhüllten viren und verfahren zu seiner herstellung Expired - Lifetime DE60222296T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/006,671 US7195905B2 (en) 2001-12-10 2001-12-10 Enveloped virus vaccine and method for production
US6671 2001-12-10
PCT/EP2002/014009 WO2003049765A2 (en) 2001-12-10 2002-12-10 Enveloped virus vaccine and method for production

Publications (2)

Publication Number Publication Date
DE60222296D1 true DE60222296D1 (de) 2007-10-18
DE60222296T2 DE60222296T2 (de) 2008-06-05

Family

ID=21722030

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222296T Expired - Lifetime DE60222296T2 (de) 2001-12-10 2002-12-10 Impfstoff von umhüllten viren und verfahren zu seiner herstellung

Country Status (7)

Country Link
US (4) US7195905B2 (de)
EP (1) EP1453535B1 (de)
AT (1) ATE372129T1 (de)
AU (1) AU2002361382B2 (de)
DE (1) DE60222296T2 (de)
NZ (1) NZ533869A (de)
WO (1) WO2003049765A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
DK1499348T3 (en) * 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2517181C (en) 2003-02-25 2013-07-16 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
GB0524782D0 (en) * 2005-12-05 2006-01-11 Chiron Srl Analysis of samples
US8673613B2 (en) * 2007-06-18 2014-03-18 Medimmune, Llc Influenza B viruses having alterations in the hemaglutinin polypeptide
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
EP3601543A4 (de) * 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. Zugabe von nukleasen direkt zur zellkultur zur erleichterung der verdauung und freisetzung von wirtszellnukleinsäuren
TWI650398B (zh) 2017-12-08 2019-02-11 Chi Mei Corporation 發光材料與應用之顯示裝置
US20240241020A1 (en) * 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
DE69535940D1 (de) 1994-11-10 2009-06-04 Baxter Healthcare Sa Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
DE60135983D1 (de) 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln

Also Published As

Publication number Publication date
US20170035874A9 (en) 2017-02-09
EP1453535B1 (de) 2007-09-05
AU2002361382B2 (en) 2008-06-12
EP1453535A2 (de) 2004-09-08
US7195905B2 (en) 2007-03-27
NZ533869A (en) 2007-02-23
WO2003049765A3 (en) 2003-10-02
US20030108859A1 (en) 2003-06-12
US20160199478A1 (en) 2016-07-14
AU2002361382A1 (en) 2003-06-23
WO2003049765A2 (en) 2003-06-19
US20070141617A1 (en) 2007-06-21
DE60222296T2 (de) 2008-06-05
US20130078261A1 (en) 2013-03-28
ATE372129T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
AU2002355677A1 (en) Antigenic polypeptides
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DE60226911D1 (de) Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
WO2003039470A3 (en) Polyvalent immunogen of hiv
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
BR0017052B1 (pt) Método para a projeção de um constructo poliepitópico e constructo poliepitópico preparado pelo referido método
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
EP1301208A4 (de) Impfstoff
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
DK0975360T3 (da) Bovint respiratorisk og enterisk coronavirus som vaccine
DE60231821D1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
EP1667634A4 (de) Anthrax-vakzine
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
WO2001092321A3 (en) Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes
ATE348888T1 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition